| scholarly article | Q13442814 |
| P50 | author | Inger Helene Madshus | Q104713688 |
| P2093 | author name string | Nina Marie Pedersen | |
| Espen Stang | |||
| Camilla Haslekås | |||
| P433 | issue | 3 | |
| P304 | page(s) | 491-500 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent | |
| P478 | volume | 6 |
| Q37251593 | A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2. |
| Q34430965 | A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. |
| Q34690918 | Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo |
| Q33820676 | ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. |
| Q34729947 | Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. |
| Q41773399 | Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells |
| Q36983366 | Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. |
| Q38717175 | MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701. |
| Q37148772 | Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab |
| Q92376425 | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer |
| Q53135719 | Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes. |
| Q90886367 | Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation |
| Q37295377 | Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins |
| Q33444766 | Regulation of ErbB2 receptor status by the proteasomal DUB POH1. |
| Q64289807 | SORLA regulates endosomal trafficking and oncogenic fitness of HER2 |
| Q38780521 | Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells |
| Q31107044 | The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments |
| Q30535295 | The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling |
| Q38237727 | The Mysterious Ways of ErbB2/HER2 Trafficking |
| Q93196147 | The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer |
| Q37328804 | The glucose transporter 2 undergoes plasma membrane endocytosis and lysosomal degradation in a secretagogue-dependent manner. |
| Q34127212 | The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression |
| Q38100745 | The significance of heat shock proteins in breast cancer therapy. |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q51547855 | Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. |
| Q36782465 | p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy |
Search more.